NR 546 Midterm Exam - PMHNP Psychopharmacology Chamberlain University | 2026-2027
NR 546 / NR546 Midterm Exam
Tested Questions with Revised Answers
PMHNP Psychopharmacology | Chamberlain University
Latest Edition - A+ Guarantee
Total Questions: 80 Format: Multiple Choice (A-D)
Cognitive Levels: 30% Recall, 50% Application, Question Style: 70% Scenario-based, 20% Direct
20% Analysis Recall, 10% Clinical Analysis
Sections: 7 comprehensive sections Aligned With: Chamberlain NR 546 Curriculum &
PMHNP Competencies
Instructions: Select the single best answer for each question. Each question has exactly one correct response. The
correct answer is marked with [CORRECT] and followed by a detailed rationale explaining the advanced
psychopharmacology clinical reasoning, including neurobiology, receptor pharmacology,
pharmacokinetic/pharmacodynamic principles, clinical application, and evidence-based practice aligned with
Chamberlain University graduate-level rigor.
Section 1: Neurobiology, Neurotransmission, and Receptor Pharmacology
(Q1-Q12)
Q1: A PMHNP is explaining neurotransmission to a graduate student. Which sequence best
describes the correct order of events at a chemical synapse following an action potential arriving at
the axon terminal?
A. Neurotransmitter release → Calcium influx → Receptor binding → Reuptake.
B. Calcium influx → Vesicle fusion → Neurotransmitter release → Receptor binding → Signal
transduction. [CORRECT]
C. Receptor binding → Vesicle fusion → Calcium influx → Reuptake.
D. Reuptake → Calcium influx → Vesicle fusion → Receptor binding.
Correct Answer: B
Rationale: An action potential depolarizes the axon terminal, opening voltage-gated Ca2+ channels. Calcium influx
triggers synaptic vesicle fusion with the presynaptic membrane (via SNARE proteins), releasing neurotransmitter into
the synaptic cleft. Neurotransmitter then binds postsynaptic receptors, initiating signal transduction (either ionotropic
fast response or metabotropic GPCR cascade). Termination occurs via reuptake, enzymatic degradation, or
diffusion. Choice A misorders calcium before release. Choices C and D are physiologically incorrect sequences.
Q2: A patient with Parkinson's disease shows degeneration of dopaminergic neurons in the
substantia nigra. Which dopaminergic pathway is primarily affected, resulting in movement
impairment?
A. Mesolimbic pathway (reward and motivation).
B. Mesocortical pathway (cognition and executive function).
Page 1
,NR 546 Midterm Exam - PMHNP Psychopharmacology Chamberlain University | 2026-2027
C. Nigrostriatal pathway (motor control). [CORRECT]
D. Tuberoinfundibular pathway (prolactin regulation).
Correct Answer: C
Rationale: The nigrostriatal pathway projects from the substantia nigra pars compacta to the dorsal striatum
(caudate and putamen) and is essential for initiating and modulating voluntary movement. Degeneration of these
neurons in Parkinson's disease causes the classic motor triad of bradykinesia, rigidity, and resting tremor. Choice A
(mesolimbic) is implicated in reward and psychosis. Choice B (mesocortical) affects cognition and negative symptoms
of schizophrenia. Choice D (tuberoinfundibular) regulates prolactin; its blockade by antipsychotics causes
hyperprolactinemia. L-DOPA replaces lost dopamine in this pathway.
Q3: Which of the following neurotransmitter-receptor pairings is correctly matched with its
downstream signaling mechanism?
A. GABA-A receptor → G-protein coupled receptor → inhibitory.
B. 5-HT1A receptor → Gs-coupled → increases cAMP.
C. Alpha-2 receptor → Gi-coupled → decreases cAMP (inhibitory autoreceptor). [CORRECT]
D. NMDA receptor → Gq-coupled → increases IP3/DAG.
Correct Answer: C
Rationale: Alpha-2 adrenergic receptors are Gi-coupled GPCRs that inhibit adenylyl cyclase, decreasing cAMP and
producing inhibitory effects. As presynaptic autoreceptors, they reduce norepinephrine release—clonidine and
guanfacine exploit this mechanism to treat ADHD and hypertension. Choice A is incorrect—GABA-A is a
ligand-gated chloride channel, not a GPCR. Choice B is incorrect—5-HT1A is Gi-coupled (decreases cAMP), not Gs.
Choice D is incorrect—NMDA is a ligand-gated ion channel (Ca2+ flux), not a GPCR; Gq-coupled receptors include
5-HT2A, alpha-1, and M1.
Q4: A PMHNP is selecting an antipsychotic and understands that 5-HT2A antagonism contributes
to the atypical profile of second-generation antipsychotics. Which receptor does 5-HT2A
antagonism indirectly enhance in the mesocortical pathway, improving negative symptoms of
schizophrenia?
A. Glutamate release in the prefrontal cortex.
B. Dopamine release in the prefrontal cortex (improving negative/cognitive symptoms).
[CORRECT]
C. GABA release in the limbic system.
D. Acetylcholine release in the hippocampus.
Correct Answer: B
Rationale: 5-HT2A receptors on dopaminergic neurons in the ventral tegmental area (VTA) are inhibitory on
dopamine release. Blocking 5-HT2A disinhibits dopamine neurons projecting to the prefrontal cortex (mesocortical
pathway), increasing prefrontal dopamine—this improves negative and cognitive symptoms of schizophrenia.
Simultaneously, 5-HT2A antagonism reduces D2 blockade requirements in the mesolimbic pathway, lowering EPS
risk. This is the basis of atypical antipsychotic pharmacology (Meltzer hypothesis). Choice A is incorrect—glutamate
is indirectly affected but not the primary mechanism. Choices C and D are unrelated to atypical antipsychotic action.
Q5: A patient taking a medication that blocks H1 receptors reports significant daytime sedation.
Which CNS role of histamine best explains why H1 blockade produces sedation?
A. Histamine promotes wakefulness and arousal via tuberomammillary nucleus projections.
[CORRECT]
B. Histamine inhibits wakefulness via the raphe nuclei.
C. Histamine stimulates gastric acid secretion in the CNS.
Page 2
, NR 546 Midterm Exam - PMHNP Psychopharmacology Chamberlain University | 2026-2027
D. Histamine regulates prolactin release from the pituitary.
Correct Answer: A
Rationale: Histaminergic neurons originate in the tuberomammillary nucleus (TMN) of the posterior hypothalamus
and project throughout the CNS to promote wakefulness, arousal, and attention. H1 receptor blockade (by
mirtazapine, olanzapine, quetiapine, diphenhydramine, doxepin) produces sedation and is exploited for sleep
induction. Choice B is incorrect—histamine PROMOTES wakefulness. Choice C describes peripheral H2 receptors
(gastric acid), not CNS effects. Choice D is incorrect—prolactin is regulated by dopamine (tuberoinfundibular). H1
blockade also causes weight gain via appetite stimulation.
Q6: A patient is prescribed a medication that acts as a partial agonist at the D2 receptor. Which of
the following best describes the pharmacologic property of a partial agonist?
A. It binds the receptor but produces no effect, blocking full agonists.
B. It produces a maximal effect greater than the endogenous ligand.
C. It produces submaximal effect even at full receptor occupancy and can act as an antagonist in
the presence of a full agonist. [CORRECT]
D. It irreversibly binds the receptor, requiring new receptor synthesis.
Correct Answer: C
Rationale: A partial agonist (e.g., aripiprazole, buprenorphine) has lower intrinsic activity than a full agonist. It
produces a submaximal response even when all receptors are occupied. In the presence of high endogenous dopamine
(e.g., during psychosis), it acts functionally as an antagonist (reducing dopaminergic overactivity). In the presence of
low dopamine (e.g., in prefrontal cortex), it acts as an agonist (boosting dopaminergic tone). This 'stabilizer' property
explains aripiprazole's efficacy with low EPS and minimal metabolic effects. Choice A describes a neutral
antagonist. Choice B is impossible (partial agonists have LOWER maximal effect). Choice D describes irreversible
antagonists.
Q7: Which of the following correctly describes the mechanism of the GABA-A receptor, the target
of benzodiazepines?
A. G-protein coupled receptor that increases cAMP.
B. Ligand-gated chloride channel that, when activated, allows Cl- influx causing neuronal
hyperpolarization (inhibitory). [CORRECT]
C. Ligand-gated sodium channel causing neuronal depolarization.
D. Ligand-gated calcium channel causing neurotransmitter release.
Correct Answer: B
Rationale: GABA-A is a ligand-gated chloride (Cl-) channel. When GABA binds, the channel opens and Cl- flows
into the neuron down its concentration gradient, causing membrane hyperpolarization and reducing neuronal
excitability—the primary fast inhibitory mechanism in the brain. Benzodiazepines are positive allosteric
modulators—they bind between alpha and gamma subunits, increasing the frequency of Cl- channel opening (not the
duration—that's barbiturates). Choice A describes GABA-B (GPCR, Gi-coupled). Choice C describes excitatory
channels. Choice D describes presynaptic voltage-gated Ca2+ channels.
Q8: A PMHNP is studying receptor regulation. Following chronic administration of an SSRI,
postsynaptic serotonin receptors decrease in number (downregulation). What is the clinical
significance of this finding?
A. Downregulation explains why SSRIs cause immediate symptom relief within hours.
B. Downregulation of 5-HT1A autoreceptors and postsynaptic receptors correlates with the delayed
therapeutic effect of SSRIs (2-4 weeks). [CORRECT]
C. Downregulation indicates medication failure and requires switching agents.
Page 3
NR 546 / NR546 Midterm Exam
Tested Questions with Revised Answers
PMHNP Psychopharmacology | Chamberlain University
Latest Edition - A+ Guarantee
Total Questions: 80 Format: Multiple Choice (A-D)
Cognitive Levels: 30% Recall, 50% Application, Question Style: 70% Scenario-based, 20% Direct
20% Analysis Recall, 10% Clinical Analysis
Sections: 7 comprehensive sections Aligned With: Chamberlain NR 546 Curriculum &
PMHNP Competencies
Instructions: Select the single best answer for each question. Each question has exactly one correct response. The
correct answer is marked with [CORRECT] and followed by a detailed rationale explaining the advanced
psychopharmacology clinical reasoning, including neurobiology, receptor pharmacology,
pharmacokinetic/pharmacodynamic principles, clinical application, and evidence-based practice aligned with
Chamberlain University graduate-level rigor.
Section 1: Neurobiology, Neurotransmission, and Receptor Pharmacology
(Q1-Q12)
Q1: A PMHNP is explaining neurotransmission to a graduate student. Which sequence best
describes the correct order of events at a chemical synapse following an action potential arriving at
the axon terminal?
A. Neurotransmitter release → Calcium influx → Receptor binding → Reuptake.
B. Calcium influx → Vesicle fusion → Neurotransmitter release → Receptor binding → Signal
transduction. [CORRECT]
C. Receptor binding → Vesicle fusion → Calcium influx → Reuptake.
D. Reuptake → Calcium influx → Vesicle fusion → Receptor binding.
Correct Answer: B
Rationale: An action potential depolarizes the axon terminal, opening voltage-gated Ca2+ channels. Calcium influx
triggers synaptic vesicle fusion with the presynaptic membrane (via SNARE proteins), releasing neurotransmitter into
the synaptic cleft. Neurotransmitter then binds postsynaptic receptors, initiating signal transduction (either ionotropic
fast response or metabotropic GPCR cascade). Termination occurs via reuptake, enzymatic degradation, or
diffusion. Choice A misorders calcium before release. Choices C and D are physiologically incorrect sequences.
Q2: A patient with Parkinson's disease shows degeneration of dopaminergic neurons in the
substantia nigra. Which dopaminergic pathway is primarily affected, resulting in movement
impairment?
A. Mesolimbic pathway (reward and motivation).
B. Mesocortical pathway (cognition and executive function).
Page 1
,NR 546 Midterm Exam - PMHNP Psychopharmacology Chamberlain University | 2026-2027
C. Nigrostriatal pathway (motor control). [CORRECT]
D. Tuberoinfundibular pathway (prolactin regulation).
Correct Answer: C
Rationale: The nigrostriatal pathway projects from the substantia nigra pars compacta to the dorsal striatum
(caudate and putamen) and is essential for initiating and modulating voluntary movement. Degeneration of these
neurons in Parkinson's disease causes the classic motor triad of bradykinesia, rigidity, and resting tremor. Choice A
(mesolimbic) is implicated in reward and psychosis. Choice B (mesocortical) affects cognition and negative symptoms
of schizophrenia. Choice D (tuberoinfundibular) regulates prolactin; its blockade by antipsychotics causes
hyperprolactinemia. L-DOPA replaces lost dopamine in this pathway.
Q3: Which of the following neurotransmitter-receptor pairings is correctly matched with its
downstream signaling mechanism?
A. GABA-A receptor → G-protein coupled receptor → inhibitory.
B. 5-HT1A receptor → Gs-coupled → increases cAMP.
C. Alpha-2 receptor → Gi-coupled → decreases cAMP (inhibitory autoreceptor). [CORRECT]
D. NMDA receptor → Gq-coupled → increases IP3/DAG.
Correct Answer: C
Rationale: Alpha-2 adrenergic receptors are Gi-coupled GPCRs that inhibit adenylyl cyclase, decreasing cAMP and
producing inhibitory effects. As presynaptic autoreceptors, they reduce norepinephrine release—clonidine and
guanfacine exploit this mechanism to treat ADHD and hypertension. Choice A is incorrect—GABA-A is a
ligand-gated chloride channel, not a GPCR. Choice B is incorrect—5-HT1A is Gi-coupled (decreases cAMP), not Gs.
Choice D is incorrect—NMDA is a ligand-gated ion channel (Ca2+ flux), not a GPCR; Gq-coupled receptors include
5-HT2A, alpha-1, and M1.
Q4: A PMHNP is selecting an antipsychotic and understands that 5-HT2A antagonism contributes
to the atypical profile of second-generation antipsychotics. Which receptor does 5-HT2A
antagonism indirectly enhance in the mesocortical pathway, improving negative symptoms of
schizophrenia?
A. Glutamate release in the prefrontal cortex.
B. Dopamine release in the prefrontal cortex (improving negative/cognitive symptoms).
[CORRECT]
C. GABA release in the limbic system.
D. Acetylcholine release in the hippocampus.
Correct Answer: B
Rationale: 5-HT2A receptors on dopaminergic neurons in the ventral tegmental area (VTA) are inhibitory on
dopamine release. Blocking 5-HT2A disinhibits dopamine neurons projecting to the prefrontal cortex (mesocortical
pathway), increasing prefrontal dopamine—this improves negative and cognitive symptoms of schizophrenia.
Simultaneously, 5-HT2A antagonism reduces D2 blockade requirements in the mesolimbic pathway, lowering EPS
risk. This is the basis of atypical antipsychotic pharmacology (Meltzer hypothesis). Choice A is incorrect—glutamate
is indirectly affected but not the primary mechanism. Choices C and D are unrelated to atypical antipsychotic action.
Q5: A patient taking a medication that blocks H1 receptors reports significant daytime sedation.
Which CNS role of histamine best explains why H1 blockade produces sedation?
A. Histamine promotes wakefulness and arousal via tuberomammillary nucleus projections.
[CORRECT]
B. Histamine inhibits wakefulness via the raphe nuclei.
C. Histamine stimulates gastric acid secretion in the CNS.
Page 2
, NR 546 Midterm Exam - PMHNP Psychopharmacology Chamberlain University | 2026-2027
D. Histamine regulates prolactin release from the pituitary.
Correct Answer: A
Rationale: Histaminergic neurons originate in the tuberomammillary nucleus (TMN) of the posterior hypothalamus
and project throughout the CNS to promote wakefulness, arousal, and attention. H1 receptor blockade (by
mirtazapine, olanzapine, quetiapine, diphenhydramine, doxepin) produces sedation and is exploited for sleep
induction. Choice B is incorrect—histamine PROMOTES wakefulness. Choice C describes peripheral H2 receptors
(gastric acid), not CNS effects. Choice D is incorrect—prolactin is regulated by dopamine (tuberoinfundibular). H1
blockade also causes weight gain via appetite stimulation.
Q6: A patient is prescribed a medication that acts as a partial agonist at the D2 receptor. Which of
the following best describes the pharmacologic property of a partial agonist?
A. It binds the receptor but produces no effect, blocking full agonists.
B. It produces a maximal effect greater than the endogenous ligand.
C. It produces submaximal effect even at full receptor occupancy and can act as an antagonist in
the presence of a full agonist. [CORRECT]
D. It irreversibly binds the receptor, requiring new receptor synthesis.
Correct Answer: C
Rationale: A partial agonist (e.g., aripiprazole, buprenorphine) has lower intrinsic activity than a full agonist. It
produces a submaximal response even when all receptors are occupied. In the presence of high endogenous dopamine
(e.g., during psychosis), it acts functionally as an antagonist (reducing dopaminergic overactivity). In the presence of
low dopamine (e.g., in prefrontal cortex), it acts as an agonist (boosting dopaminergic tone). This 'stabilizer' property
explains aripiprazole's efficacy with low EPS and minimal metabolic effects. Choice A describes a neutral
antagonist. Choice B is impossible (partial agonists have LOWER maximal effect). Choice D describes irreversible
antagonists.
Q7: Which of the following correctly describes the mechanism of the GABA-A receptor, the target
of benzodiazepines?
A. G-protein coupled receptor that increases cAMP.
B. Ligand-gated chloride channel that, when activated, allows Cl- influx causing neuronal
hyperpolarization (inhibitory). [CORRECT]
C. Ligand-gated sodium channel causing neuronal depolarization.
D. Ligand-gated calcium channel causing neurotransmitter release.
Correct Answer: B
Rationale: GABA-A is a ligand-gated chloride (Cl-) channel. When GABA binds, the channel opens and Cl- flows
into the neuron down its concentration gradient, causing membrane hyperpolarization and reducing neuronal
excitability—the primary fast inhibitory mechanism in the brain. Benzodiazepines are positive allosteric
modulators—they bind between alpha and gamma subunits, increasing the frequency of Cl- channel opening (not the
duration—that's barbiturates). Choice A describes GABA-B (GPCR, Gi-coupled). Choice C describes excitatory
channels. Choice D describes presynaptic voltage-gated Ca2+ channels.
Q8: A PMHNP is studying receptor regulation. Following chronic administration of an SSRI,
postsynaptic serotonin receptors decrease in number (downregulation). What is the clinical
significance of this finding?
A. Downregulation explains why SSRIs cause immediate symptom relief within hours.
B. Downregulation of 5-HT1A autoreceptors and postsynaptic receptors correlates with the delayed
therapeutic effect of SSRIs (2-4 weeks). [CORRECT]
C. Downregulation indicates medication failure and requires switching agents.
Page 3
